Cargando…

Comparative Proteomics Analysis Reveals the Reversal Effect of Cryptotanshinone on Gefitinib-Resistant Cells in Epidermal Growth Factor Receptor-Mutant Lung Cancer

Cryptotanshinone (CTS) is a lipophilic constituent of Salvia miltiorrhiza, with a broad-spectrum anticancer activity. We have observed that CTS enhances the efficacy of gefitinib in human lung cancer H1975 cells, yet little is known about its molecular mechanism. To explore how CTS enhances H1975 ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Peiheng, Sheng, Gaofan, Jiang, Shiqin, Wang, Daifei, Zhao, Zhongxiang, Huang, Min, Jin, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965640/ https://www.ncbi.nlm.nih.gov/pubmed/35370706 http://dx.doi.org/10.3389/fphar.2022.837055

Ejemplares similares

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
por: Xu, Chuncao, et al.
Publicado: (2021)

Integrated Proteomics and Metabolomics Link Acne to the Action Mechanisms of Cryptotanshinone Intervention
por: Zhu, Zhaoming, et al.
Publicado: (2021)

Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System
por: Hong, Weipeng, et al.
Publicado: (2018)

Preparation and optimization of surface stabilized cryptotanshinone nanocrystals with enhanced bioavailability
por: Zhao, Wenzheng, et al.
Publicado: (2023)

Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma
por: Luo, Yi, et al.
Publicado: (2020)

Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review
por: Dalil, Davood, et al.
Publicado: (2022)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
por: He, Xiangjun, et al.
Publicado: (2023)

Cryptotanshinone Inhibits the Growth of HCT116 Colorectal Cancer Cells Through Endoplasmic Reticulum Stress-Mediated Autophagy
por: Fu, Xiaojing, et al.
Publicado: (2021)

Synergistic Effects of Cryptotanshinone and Senkyunolide I in Guanxinning Tablet Against Endogenous Thrombus Formation in Zebrafish
por: Li, Jun, et al.
Publicado: (2021)

Novel perspectives on the therapeutic role of cryptotanshinone in the management of stem cell behaviors for high-incidence diseases
por: Guo, Xiaomeng, et al.
Publicado: (2022)

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
por: Cheng, Haibo, et al.
Publicado: (2018)

Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms
por: Li, Huayao, et al.
Publicado: (2021)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
por: Liu, Dongcheng, et al.
Publicado: (2022)

Cellular photo(geno)toxicity of gefitinib after biotransformation
por: El Ouardi, Meryem, et al.
Publicado: (2023)

Cryptotanshinone protects skin cells from ultraviolet radiation-induced photoaging via its antioxidant effect and by reducing mitochondrial dysfunction and inhibiting apoptosis
por: Guo, Keke, et al.
Publicado: (2022)

Cryptotanshinone Attenuates Airway Remodeling by Inhibiting Crosstalk Between Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and Transforming Growth Factor Beta 1 Signaling Pathways in Asthma
por: Wang, Chongyang, et al.
Publicado: (2019)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects
por: Zhang, Hong, et al.
Publicado: (2018)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

Cryptotanshinone affects HFL-1 cells proliferation by inhibiting cytokines secretion in RAW264.7 cells and ameliorates inflammation and fibrosis in newborn rats with hyperoxia induced lung injury
por: Ma, Mengmeng, et al.
Publicado: (2023)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Cryptotanshinone Reverses Reproductive and Metabolic Disturbances in PCOS Model Rats via Regulating the Expression of CYP17 and AR
por: Yu, Jin, et al.
Publicado: (2014)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
por: Sheng, Lili, et al.
Publicado: (2021)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Neuroregeneration of injured peripheral nerve by fraction B of catfish epidermal secretions through the reversal of the apoptotic pathway and DNA damage
por: Al-Arbeed, Taiba A., et al.
Publicado: (2023)

Modulation of Pathological Pain by Epidermal Growth Factor Receptor
por: Borges, Jazlyn P., et al.
Publicado: (2021)

Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
por: Kim, Mi Seong, et al.
Publicado: (2020)

The Influence of Selected Factors on the Aqueous Cryptotanshinone Solubility
por: Kobryń, Justyna, et al.
Publicado: (2021)

Cryptotanshinone Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ in Chronic Obstructive Pulmonary Disease
por: Xie, Tao, et al.
Publicado: (2023)

Proteomic analyses reveal that ginsenoside Rg3(S) partially reverses cellular senescence in human dermal fibroblasts by inducing peroxiredoxin
por: Jang, Ik-Soon, et al.
Publicado: (2020)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

Taurine and Epidermal Growth Factor Belong to the Signature of First-Episode Psychosis
por: Koido, Kati, et al.
Publicado: (2016)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer
por: Ni, Wenting, et al.
Publicado: (2021)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
por: Jiang, Yuhong, et al.
Publicado: (2021)

Cryptotanshinone Ameliorates Radiation-Induced Lung Injury in Rats
por: Jiang, Yifang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ctvkcvuh2nmrpo5rcsuufclfa6